[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard for advanced non-small-cell lung cancer (NSCLC) with EGFR mutations.
• Gefitinib, erlotinib, and icotinib were initial first-line EGFR-TKIs.
• Newer EGFR-TKIs like afatinib and AZD9291 expand first-line treatment options.

Purpose of the Study:

• To review precision first-line therapy for advanced NSCLC patients with EGFR mutations.
• To discuss the evolving landscape of EGFR-TKIs in NSCLC treatment.
• To highlight the role of gene detection in understanding NSCLC and drug resistance.

Main Methods:

• Literature review of clinical trial results and practice guidelines.
• Analysis of emerging EGFR-TKIs and their efficacy.
• Discussion of advancements in gene detection technology for NSCLC.

Main Results:

• Multiple first-line EGFR-TKI options are now available for EGFR-mutated NSCLC.
• Advancements in gene detection provide deeper insights into NSCLC.
• Understanding drug resistance mechanisms is crucial for treatment optimization.

Conclusions:

• Precision medicine, guided by EGFR mutation status, is key for advanced NSCLC.
• The selection of first-line EGFR-TKIs is becoming more personalized.
• Ongoing research in TKIs and diagnostics will further refine NSCLC treatment strategies.